Assessment of disease activity of Graves’ ophthalmopathy

  • Mark F. Prummel
  • Wilmar M. Wiersinga
  • Maarten Ph. Mourits

Abstract

The concept of disease activity originates from observations of the natural course of the eye signs in patients left untreated for the ophthalmopathy, and from a small number of histologic studies performed on orbital tissues from patients with variable duration of the eye disease.

Keywords

Corticosteroid Adenoma Glucocorticoid Cyclosporine Prednisone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kessel L, Hyman HT, Lande H. A study of fifty consecutive cases of exophthalmic goiter. Arch Int Med 1923; 31: 433–454.CrossRefGoogle Scholar
  2. 2.
    Copper AC. An introduction to clinical orbitonometry. Thesis University of Leiden 1948Google Scholar
  3. 3.
    Rundle FF. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Cli Sci 1945; 5: 177–194.Google Scholar
  4. 4.
    Rundle FF. Management of exophthalmos and related ocular changes in Graves’ disease. Metabolism 1957; 6: 36–48.PubMedGoogle Scholar
  5. 5.
    Dobyns BM. Present concepts of the pathologic physiology of exopthalmos. J Clin Endocrinol Metab 1950; 10: 1202–1230.PubMedCrossRefGoogle Scholar
  6. 6.
    Rundle FF. Ocular changes in Graves’ disease. Q J Med 1960; 29: 113–126.PubMedGoogle Scholar
  7. 7.
    Streeten DHP, Anderson GH, Reed GF, Woo P. Prevalence, natural history and surgical treatment of exophthalmos. Clin Endocrinol 1987; 27: 125–133.CrossRefGoogle Scholar
  8. 8.
    Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 1995; 42: 45–50.CrossRefGoogle Scholar
  9. 9.
    Hamilton HE, Schultz RO, De Gowin EL. The endocrine eye lesion in hyperthyroidism. Arch Int Med 1960; 105: 675–685.CrossRefGoogle Scholar
  10. 10.
    Bartley GB, Fatourechi V, Kadrmas EF. et al. Long-term follow-up of Graves Ophthalmopathy in an incidence cohort. Ophthalmology 1996; 103: 958–962.PubMedGoogle Scholar
  11. 11.
    Burch H, Wartofsky L. Graves’ ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747–793.PubMedGoogle Scholar
  12. 12.
    Naffziger HC. Pathologic changes in the orbit in progressive exophthalmos. Arch Ophthalmol 1933; 9: 1–12.CrossRefGoogle Scholar
  13. 13.
    Dunnington JH, Berke RN. Exophthalmos due to chronic orbital myositis. Arch Ophthalmol 1943; 30: 446–466.CrossRefGoogle Scholar
  14. 14.
    Brain RW. Exophthalmic ophthalmoplegia. Q J Med 1938; 31: 293–323.Google Scholar
  15. 15.
    Daicker B. Das gewebliche Substrat der verdickten ausseren Augenmuskeln bei der endokrinen Orbitopathie. Klin Mbl Augenheilk 1979; 174: 843–847.PubMedGoogle Scholar
  16. 16.
    Rundle FF, Finlay-Jones LR, Noad KB. Malignant exophthalmos: a quantitative analysis of the orbital tissues. Australasian Ann Med 1953; 2: 1–8.Google Scholar
  17. 17.
    Hufnagel TJ, Hickey WF, Cobbs WH, Jakobiec FA, Iwamoto T, Eagle RC. Immunohistochemical and ultrastrucural studies on the exenterated orbital tissues of a patient with Graves’ disease. Ophthalmology 1984; 91: 1411–1419.PubMedGoogle Scholar
  18. 18.
    Kroll AJ, Kuwabara T. Dysthyroid ocular myopathy. Arch Ophthalmol 1966; 76: 244–257.PubMedCrossRefGoogle Scholar
  19. 19.
    Tallstedt L, Norberg R. Immunohistochemical staining of normal and Graves’ extraocular muscle. Inv Ophthalmol Vis Sc 1988; 29: 175–184.Google Scholar
  20. 20.
    Gayno JP, Strauch G. Cyclosporine and Graves’ ophthalmopathy. Horm Res 1987; 26: 190–197.PubMedCrossRefGoogle Scholar
  21. 21.
    Van der Gaag R, Wiersinga WM, Koornneef L. et al. HLA-DR4 associated response to corticosteroids in Graves’ ophthalmopathy patients. J Endocrinol Invest 1990; 13: 489–492.PubMedGoogle Scholar
  22. 22.
    Preus M, Frecker MF, Stenszky V, Balazs C, Farid NR. A prognostic score for Graves’ disease. Clin Endocrinol 1985; 23: 653–661.CrossRefGoogle Scholar
  23. 23.
    Prummel MF, Mourits MP, Berghout A. et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 1989; 321: 1353–1359.PubMedCrossRefGoogle Scholar
  24. 24.
    Prummel MF, Mourits MP, Blank L. et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 1993; 342: 949–954.PubMedCrossRefGoogle Scholar
  25. 25.
    Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 1973; 37: 276–285.PubMedCrossRefGoogle Scholar
  26. 26.
    Bartalena L, Marcocci C, Chiovato L. et al. Orbital Cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: Comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56: 1139–1144.PubMedCrossRefGoogle Scholar
  27. 27.
    Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991; 14: 853–860.PubMedGoogle Scholar
  28. 28.
    Musch DC, Frueh BR, Landis R. The reliability of Hertel exophthalmometry. Observer variation between physician and lay readers. Ophthalmology 1985; 92: 1177–1180.PubMedGoogle Scholar
  29. 29.
    Van Dijk HJL. Orbital Graves’ disease. A modification of the “NO SPECS” classification. Ophthalmology 1981; 88: 479–483.Google Scholar
  30. 30.
    Sergott RC, Felberg NT, Savino PJ, Blizzard JJ, Schatz NJ. Graves’ ophthalmopathy-immunologic parameters related to corticosteroid therapy. Invest Ophthalmol Vis Sci 1981; 20: 173–182.PubMedGoogle Scholar
  31. 31.
    Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. British Journal of Ophthalmology 1989; 73: 639–644.PubMedCrossRefGoogle Scholar
  32. 32.
    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997; 47: 9–14.CrossRefGoogle Scholar
  33. 33.
    Rose GE. Commentary. Clinical activity score as a guide in the management of patients with Graves’ orbitopathy. Clin Endocrinol 1996; 47: 15CrossRefGoogle Scholar
  34. 34.
    Lane C, Feyi-Wabosa A, Lazarus J. A simple scoring system for thyroid eye disease. Abstract book VIth International Symposium on Graves’ Ophthalmopathy, Amsterdam 1998; 13(Abstract)Google Scholar
  35. 35.
    Armstrong P, Keevil SF. Magnetic resonance imaging-1: basic principles of image production. Br Med J 1991; 303: 35–40.CrossRefGoogle Scholar
  36. 36.
    Just M, Kahaly G, Higer HP. et al. Graves’ ophthalmopathy: Role of MR Imaging in radiation therapy. Radiology 1991; 179: 187–190.PubMedGoogle Scholar
  37. 37.
    Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves’ ophthalmopathy. Thyroid 1995; 5: 185–193.PubMedGoogle Scholar
  38. 38.
    Nakahara H, Noguchi S, Murakami N. et al. Graves’ ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids. Radiology 1995; 196: 857–862.PubMedGoogle Scholar
  39. 39.
    Laitt RD, Hoh B, Wakeley C. et al. The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol 1994; 67: 244–247.PubMedCrossRefGoogle Scholar
  40. 40.
    Hiromatsu Y, Kojima K, Ishisaka N. et al. Role of Magnetic Resonance Imaging in thyroid-associated ophthalmopathy: Its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992; 2: 299–305.PubMedCrossRefGoogle Scholar
  41. 41.
    Postema PTE, Krenning EP, Wijngaarde R. et al. [111In-DTPA-D-phel] octreotide scintigraphy in thyroidal and orbital Graves’ disease: a parameter for disease activity? J Clin Endocrinol Metab 1994; 79: 1845–1994.PubMedCrossRefGoogle Scholar
  42. 42.
    Moncayo R, Baldnisera I, Decristoforo C, Kendler D, Donnemiller E. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging the somatostatin analog 111In-octreotide. Thyroid 1997; 7: 21–29.PubMedCrossRefGoogle Scholar
  43. 43.
    Kahaly G, Diaz M, Just M, Beyer J, Lieb W. Role of octreoscan and correlation with MR Imaging in Graves’ ophthalmopathy. Thyroid 1995; 5: 107–111.PubMedCrossRefGoogle Scholar
  44. 44.
    Kahaly G, Diaz M, Haka K, Beyer J, Bockisch A. Indium-111-pentetreotide scintigraphy in Graves’ ophthalmopathy. J Nucl Med 1995; 36: 550–554.PubMedGoogle Scholar
  45. 45.
    Wiersinga WM, Gerding MN, Prummel MF, Krenning EP. Octreotide scintigraphy in thyroidal and orbital Graves’ disease. Thyroid 1998; 8: 433–436.PubMedCrossRefGoogle Scholar
  46. 46.
    Kahaly G, Gorges R, Diaz M, Hommel G, Bockisch A. Indium-111-Pentetreotide in Graves’ disease. J Nucl Med 1998; 39: 533–536.PubMedGoogle Scholar
  47. 47.
    Gerding MN, Van der Zant FM, Van Royen EA. et al. Octreotide-scintigraphy is a disease activity parameter in Graves’ ophthalmopathy. Clin Endocrinol 1999; 50:373–379.CrossRefGoogle Scholar
  48. 48.
    Colao A, Lastoria S, Ferone D. et al. Orbital scintigraphy with [111In-Diethylenetriamine Pentaacetic Acid-D-Phe1-Octreotide predicts the clinical response to corticosteroid therapy in patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 3790–3794.PubMedCrossRefGoogle Scholar
  49. 49.
    Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 1995; 42: 571–580.CrossRefGoogle Scholar
  50. 50.
    Sergott RC, Glaser JS. Graves’ ophthalmopathy. A clinical and immunologic review. Surv Ophthalmol 1981; 26: 1–21.PubMedCrossRefGoogle Scholar
  51. 51.
    Prummel MF, Suttorp-Schulten MS, Wiersinga WM, Verbeek AM, Mourits MP, Koornneef L. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy. Ophthalmology 1993; 100: 556–561.PubMedGoogle Scholar
  52. 52.
    Barnes A. Measurement of serum cytokines. Lancet 1998; 352: 324–325.PubMedCrossRefGoogle Scholar
  53. 53.
    Sergott RC, Felberg NT, Savino PJ, Blizzard JJ, Schatz NJ. E-rosette formation in Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 1979; 18: 1245–1251.PubMedGoogle Scholar
  54. 54.
    Wall JR, Gray B, Greenwood DM. Total and “activated” peripheral blood T lymphocytes in patients with thyroid disorders. Acta Endocrinol (Copenh ) 1977; 85: 753–759.Google Scholar
  55. 55.
    Munro RE, Lamki L, Row VV, Volpe R. Cell-mediated immunity in the exophthalmos of Graves’ disease as demonstrated by the Migration Inhibition Factor (MIF) test. J Clin Endocrinol Metab 1973; 37: 286–292.PubMedCrossRefGoogle Scholar
  56. 56.
    Volpe R. Review The role of autoimmunity in hypoendocrine and hyperendocrine function. Ann Int Med 1977; 87: 86–99.PubMedGoogle Scholar
  57. 57.
    Van der Gaag R, Broersma L, Mourits MP. et al. Circulating monocyte migration inhibitory factor in serum of Graves’ ophthalmopathy patients: a parameter for disease activity? Clin Exp Immunol 1989; 75: 275–279.PubMedGoogle Scholar
  58. 58.
    Balazs C, Farid NR. Soluble Interleukin-2 receptor in sera of patients with Graves’ dosease. J Autoimmunity 1991; 4: 681–688.CrossRefGoogle Scholar
  59. 59.
    Prummel MF, Wiersinga WM, Van der Gaag R, Mourits MP, Koornneef L. Soluble IL-2 receptor levels in patients with Graves’ ophthalmopathy. Clin Exp Immunol 1992; 88: 405–409.PubMedCrossRefGoogle Scholar
  60. 60.
    Salvi M, Girasole G, Pedrazzoni M. et al. Increased serum concentrations of Interleukin-6 (IL-6) and soluble IL-6 Receptor in patients with Graves’ disease. J Clin Endocrinol Metab 1996; 81: 2976–2979.PubMedCrossRefGoogle Scholar
  61. 61.
    Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N. Increased serum concentration of soluble CD30 in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1997; 82: 1757–1760.PubMedCrossRefGoogle Scholar
  62. 62.
    Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) Receptor Antagonist and soluble IL-1 Receptor inihibit IL-1 induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab 1996; 81: 449–452.PubMedCrossRefGoogle Scholar
  63. 63.
    Hofbauer LC, Muhlberg T, Konig A, Heufelder G, Schworm H, Heufelder AE. Soluble Interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves’ ophthalmopathy undergoing orbital radiotherapy. J Clin Endocrinol Metab 1997; 82: 2244–2247.PubMedCrossRefGoogle Scholar
  64. 64.
    Frenette PS, Wagner DD. Molecular Medicine. Adhesion molecules — Part I. N Engl J Med 1996;334:1526–1529.PubMedCrossRefGoogle Scholar
  65. 65.
    Frenette PS, Wagner DD. Molecular medicine. Adhesion molecules — Part II: blood vessels and blood cells. N Engl J Med 1996; 335: 43–45.PubMedCrossRefGoogle Scholar
  66. 66.
    Heufelder AE, Bahn RS. Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves’ ophthalmopathy. Clin Exp Immunol 1993; 91: 381–389.PubMedCrossRefGoogle Scholar
  67. 67.
    Pappa A, Calder V, Fells P, Lightman S. Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol 1997; 108: 3069–313.CrossRefGoogle Scholar
  68. 68.
    Heufelder AE, Bahn RS. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves’ ophthalmopathy and thyroid disease. Clin Exp Immunol 1993; 92: 296–302.PubMedCrossRefGoogle Scholar
  69. 69.
    De Bellis A, Bizzarro A, Gattoni A. et al. Behavior of soluble Intercellular Adhesion Molecule-1 and Endothelial-Leukocyte Adhesion molecule-1 concentrations in patients with Graves’ disease with or without ophthalmopathy and in patients with toxic adenoma. J Clin Endocrinol Metab 1995; 80: 2118–2121.PubMedCrossRefGoogle Scholar
  70. 70.
    Prummel MF, Van Pareren Y, Bakker O, Wiersinga WM. Anti-heat shock protein (hsp) 72 antibodies are present in patients with Graves’ disease (GD) and in control smoking subjects. Clin Exp Immunol 1997; 110: 292–295.PubMedCrossRefGoogle Scholar
  71. 71.
    McGregor AM. Has the target autoantigen for Graves’ ophthalmopathy been found? Lancet 1998; 352: 595–596.PubMedCrossRefGoogle Scholar
  72. 72.
    McLachlan SM, Bahn RS, Rapoport B. Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies. Autoimmunity 1992; 14: 143–148.PubMedCrossRefGoogle Scholar
  73. 73.
    Jacobson DH, Gorman CA. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocr Rev 1984; 5: 200–220.PubMedCrossRefGoogle Scholar
  74. 74.
    Pappa A, Jackson P, Stone J. et al. An ultrastructural and systemic analysis of glycosaminoglycans in thyroid-associated ophthalmopathy. Eye 1998; 12: 237–244.PubMedCrossRefGoogle Scholar
  75. 75.
    Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 1989; 10: 366–391.PubMedCrossRefGoogle Scholar
  76. 76.
    Kahaly G, Schuler M, Sewell AC, Bernhard G, Beyer J, Krause U. Urinary glycosaminoglycans in Graves’ ophthalmopathy. Clin Endocrinol 1990; 33: 35–44.CrossRefGoogle Scholar
  77. 77.
    Martinez-Bru C, Ampudia X, Castrillo P, Gonzalez-Sastre F. Urinary glycosaminoglycans in active Graves’ ophthalmopathy. Clin Chem 1992; 38: 2341PubMedGoogle Scholar
  78. 78.
    Hansen C, Fraiture B, Rouhi R, Otto E, Forster G, Kahaly G. HPLC glycosaminoglycan analysis in patients with Graves’ disease. Cli Sci 1997; 92: 511–517.Google Scholar
  79. 79.
    Kahaly G, Forster G, Hansen C. Glycosaminoglycans in Thyroid Eye Disease. Thyroid 1998;8:429–432.PubMedCrossRefGoogle Scholar
  80. 80.
    Kahaly G, Hansen C, Beyer J, Winand R. Plasma glycosaminoglycans in endocrine ophthalmopathy. J Endocrinol Invest 1994; 17: 45–50.PubMedGoogle Scholar
  81. 81.
    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Measuring eye movements in Graves’ ophthalmopathy. Ophthalmology 1994; 101: 1341–1346.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Mark F. Prummel
    • 1
  • Wilmar M. Wiersinga
  • Maarten Ph. Mourits
  1. 1.Department of Endocrinology, F5171, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations